New study aims to personalize chemo for HIV-Linked cancer

NCT ID NCT06480773

Ongoing Knowledge-focused Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 127 people with HIV-related Kaposi sarcoma in Malawi and South Africa who are receiving standard chemotherapy (paclitaxel or bleomycin plus vincristine). Researchers want to understand why some patients respond better than others, looking at factors like gender and virus levels. The goal is to find ways to tailor treatment for better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paclitaxel or Bleomycin and Vincristine (chemotherapy)
What this could lead to: If successful, this study could help doctors personalize chemotherapy for HIV-related Kaposi sarcoma, potentially improving outcomes and reducing side effects.
What could go wrong: This is an observational study, not testing a new treatment. It may not lead to immediate changes in care, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease Kaposi's sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV KAPOSI SARCOMA

Contacts and locations

Locations

Stellenbosch University and Tygerberg Hospital

Cape Town, Stellenbosch, 8000, South Africa
UNC Project, Kamuzu Central Hospital

Lilongwe, Malawi

More trials for these conditions

Other studies related to the condition(s) this trial covers.